A detailed history of Fox Run Management, L.L.C. transactions in Regenxbio Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 13,784 shares of RGNX stock, worth $95,523. This represents 0.02% of its overall portfolio holdings.

Number of Shares
13,784
Previous 14,440 4.54%
Holding current value
$95,523
Previous $151,000 29.8%
% of portfolio
0.02%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

SELL
$7.23 - $11.56 $4,742 - $7,583
-656 Reduced 4.54%
13,784 $106,000
Q3 2024

Nov 12, 2024

BUY
$10.49 - $14.39 $151,475 - $207,791
14,440 New
14,440 $151,000
Q2 2019

Jul 17, 2019

BUY
$42.0 - $59.29 $220,080 - $310,679
5,240 New
5,240 $269,000
Q1 2019

Oct 17, 2019

SELL
$40.82 - $62.45 $447,999 - $685,388
-10,975 Closed
0 $0
Q4 2018

Jan 15, 2019

BUY
$39.11 - $75.15 $429,232 - $824,771
10,975 New
10,975 $460,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $300M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.